ICIs in preclinical GBM mouse models confirmed the safety and efficiency of monoclonal antibodies targeting the PD-1/PD-L1 axis (23), but have little clinical benefit in GBM, especially in patients harboring EGFR amplification. The gene discussed is EGFR; the disease is glioblastoma.